NSAIDs Market to Reach USD 24.35 Billion by 2027; Rising Geriatric Population Worldwide to Augment Growth

The global non-steroidal anti-inflammatory drugs (NSAIDs) market size is projected to reach USD 24.35 billion by 2027. It is set to gain impetus from the rising geriatric population across the world. It is further increasing the prevalence of chronic and acute pain. Diclofenac and ibuprofen are two of the most commonly used NSAIDs. This information is given by Fortune Business Insights™ in a recently published report, titled, “Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Size, Share & Industry Analysis, By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The report further states that the market stood at USD 15.58 billion in 2019. However, it is set to exhibit a CAGR of 5.8% during the forecast period between 2020 to 2027.

GlaxoSmithKline Bags FDA Approval for Voltaren Arthritis Pain

In February 2020, GlaxoSmithKline (GSK), a multinational pharmaceutical company headquartered in the U.K., announced that it received the USFDA approval for Voltaren Arthritis Pain. It can now be used as an over-the-counter (OTC) product to get temporary relief from arthritis pain in the knees, ankle, foot, elbow, wrist, and hands in adults belonging to the age group of 18 years and older.

The drug is the only prescription strength NSAID topical gel that is available OTC in the U.S. This approval would fulfil the company’s goal to offer the drug to more than 30 million patients living with osteoarthritis in the U.S. As stiffness and joint pain are daily realities for many people, GSK wanted to improve their quality of lives by providing easy access to OTC drugs. The new approval made it simpler.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/non-steroidal-anti-inflammatory-drugs-nsaids-market-102823

Rising Concerns Regarding Usage of Opioids to Drive Growth

Opioids and NSAIDs are the most commonly used drugs across the globe. They are mainly consumed to treat mild to severe pain. But, the usage of opioids often causes adverse events. Safety is the major concern associated with them. The number of opioids-relation deaths has surged worldwide. It is therefore receiving widespread attention. This has caused a decline in the usage of opioids and thus, people are inclining more towards NSAIDs to treat pain. According to the American Academy of Family Physicians, the usage of naproxen and ibuprofen will help in treating mild to moderate pain. Such recommendations would propel the NSAIDs market growth. However, the rising cases of NSAIDs-related gastrointestinal complications may hamper growth.

Key Manufacturers Aim to Strengthen Position by Receiving FDA Approvals

The market consists of several manufacturers. Amongst them, GSK and Pfizer hold the dominating positions. This growth is attributable to their diverse product portfolio, mergers and acquisitions, collaborations, as well as innovative product launches. They are also efficiently receiving approvals from well-known regulatory bodies for marketing their products.

Fortune Business Insights™ lists out the names of all the companies present in the NSAIDs market. They are as follows:

• Zyla Life Sciences


• GlaxoSmithKline plc


• Johnson & Johnson Services, Inc.


• Bayer AG


• AstraZeneca


• Pfizer Inc.


• Boehringer Ingelheim International GmbH


• Horizon Therapeutics plc


• Others

Significant Industry Developments-

• November 2017: Pfizer Korea, a pharmaceutical company made Celebrex, its in-house NSAID eligible for insurance benefits to every adult suffering from ankylosing spondylitis, rheumatoid arthritis, and osteoarthritis. The drug lowers the risk of gastrointestinal complications by acting as a protective agent during inflammation and pain.


• December 2016: Pfizer Inc. achieved the USFDA approval for its novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor named EUCRISATM (crisaborole) ointment 2%. It will be used to treat patients suffering from mild to moderate atopic dermatitis (AD). However, it will be applicable in patients who are two years of age and older.

Further Report Findings-

• North America generated USD 6.86 billion in 2019 in terms of revenue. This growth is attributable to the increased research, rising incidence of arthritis, and presence of numerous industry giants in this region.


• Europe is set to grow significantly backed by the favorable health reimbursement policies, rising prevalence of migraine, and active government support.


• Based on disease indication, the arthritis segment held 37.9% NSAIDs market share in 2019 owing to the higher cases of osteoarthritis and rheumatoid arthritis worldwide.

The global NSAIDs market can be segmented in the following way: